info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Indications for Trabectedin (Yondelis)?
505
Article source: Seagull Pharmacy
Dec 09, 2025

Trabectedin (Yondelis) is an innovative alkylating agent. As an important anti-tumor treatment option, it plays a key role in the therapy of soft tissue sarcomas.

What Are the Indications for Trabectedin (Yondelis)?

Primary Therapeutic Indications

Trabectedin is approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received an anthracycline-containing treatment regimen.

Characteristics of Applicable Populations

Disease status: Locally advanced or metastatic lesions.

Histological type: Liposarcoma (including dedifferentiated, myxoid round cell, or pleomorphic subtypes) or leiomyosarcoma.

Treatment history: Must have specific prior treatment experience.

Specifications and Properties of Trabectedin (Yondelis)

Basic Drug Characteristics

Dosage form: Injection.

Packaging form: Single-dose vial.

Specification and content: Each vial contains 1 mg of trabectedin.

Physical Properties

Appearance: White to off-white lyophilized powder/cake.

Reconstituted solution: Clear, colorless to pale tan.

Composition

Active ingredient: Trabectedin.

Excipients:

Potassium dihydrogen phosphate: 27.2 mg.

Sucrose: 400 mg.

Phosphoric acid and potassium hydroxide (used to adjust pH to 3.6–4.2).

Chemical Properties

Trabectedin is an alkylating agent, with the chemical name (1'R,6R,6aR,7R,13S,14S,16R)-5(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-19-one.

Its molecular formula is C₃₉H₄₃N₃O₁₁S, with a molecular weight of 761.84 daltons.

Storage and Handling Methods of Trabectedin (Yondelis)

Storage Requirements

Must be stored in a refrigerated environment at 2°C to 8°C (36°F to 46°F).

Freezing is strictly prohibited.

Environmental Protection

Should be kept in the original carton to protect from light exposure.

Follow special handling and disposal procedures for hazardous drugs.

Reconstitution Steps

Using aseptic technique, inject 20 mL of sterile water for injection into the vial.

Shake the vial until completely dissolved.

The concentration of the reconstituted solution is 0.05 mg/mL.

Solution Inspection

The solution must be carefully inspected for particulates and discoloration before use.

The vial should be discarded if particulates or significant brown discoloration are observed.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Trabectedin(YONDELIS)
Trabectedin(YONDELIS)
It is indicated for the treatment of unresectable or metastatic liposarcoma or...
WeChat Scan
Free Inquiry
Recommended Articles
What Are the Indications for Pirfenidone (Esbriet)?
Pirfenidone (Esbriet) is an important antifibrotic drug that plays a key role in the treatment of idiopathic pulmonary fibrosis (IPF).What Are the Indications for Pirfenidone (Esbriet)?Main Therapeuti...
What Are the Purchasing Channels for Pirfenidone (Esbriet)?
Pirfenidone (Esbriet) is an important prescription medication for the treatment of idiopathic pulmonary fibrosis (IPF), playing an irreplaceable role in helping patients slow down the decline of lung ...
Adverse Reactions of Gemtuzumab (Mylotarg)
Gemtuzumab (Mylotarg) is a CD33-targeted antibody-drug conjugate indicated for the treatment of newly diagnosed or relapsed/refractory CD33-positive acute myeloid leukemia.Adverse Reactions of Gemtuzu...
What Are the Precautions for Using Gemtuzumab (Mylotarg)?
Gemtuzumab (Mylotarg) is a targeted therapy for CD33-positive acute myeloid leukemia (AML), and its use requires strict adherence to standardized clinical operating procedures and monitoring requireme...
What Are the Purchase Channels for Alemtuzumab Injection (Lemtrada)?
Alemtuzumab Injection (Lemtrada) is a cytolytic monoclonal antibody targeting CD52, indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults.What Are the Purchase Channels f...
What are the indications for Alemtuzumab Injection (Lemtrada)?
Alemtuzumab Injection (Lemtrada) is an important therapeutic drug, primarily indicated for patients with specific types of multiple sclerosis. As a CD52-directed cytolytic monoclonal antibody, this me...
Dosage and Administration, Recommended Dose of Alemtuzumab Injection (Lemtrada)
Alemtuzumab Injection (Lemtrada) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including relapsing-rem...
What are the precautions for using Alemtuzumab Injection (Lemtrada)?
Alemtuzumab Injection (Lemtrada) is a CD52-directed cytolytic monoclonal antibody, primarily indicated for the treatment of adult patients with relapsing multiple sclerosis.What are the precautions fo...
Related Articles
What Are the Indications for Trabectedin (Yondelis)?
Trabectedin (Yondelis) is an innovative alkylating agent. As an important anti-tumor treatment option, it plays a key role in the therapy of soft tissue sarcomas.What Are the Indications for Trabected...
Adverse Reactions of Trabectedin (Yondelis)
Trabectedin (Yondelis) is an alkylating antineoplastic agent that exerts its antitumor effect by binding to the minor groove of DNA. It is indicated for the treatment of unresectable or metastatic lip...
What Are the Side Effects of Trabectedin (Yondelis)?
Trabectedin (Yondelis) is an alkylating agent approved by the U.S. FDA in 2015 for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received ...
Precautions for Using Trabectedin (Yondelis)
Trabectedin (Yondelis) is a new type of alkylating agent drug. Approved for marketing in the United States in 2015, it is specifically indicated for the treatment of patients with unresectable or meta...
How to Use Trabectedin (Yondelis)
Trabectedin (Yondelis) is an alkylating agent. First approved in the United States in 2015, it is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma ...
Indications for Trabectedin (Yondelis)
Trabectedin (Yondelis) is an injectable alkylating agent approved by the U.S. Food and Drug Administration (FDA) in 2015 for clinical treatment, specifically targeting certain types of soft tissue sar...
How to Purchase Trabectedin (Yondelis)
Trabectedin (Yondelis) is a new type of alkylating agent, indicated for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received anthracycline-containing reg...
What is the Price of Trabectedin?
Trabectedin is a prescription drug used for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma. When choosing a suitable treatment plan, understanding the drug’s price is also a...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved